Docetaxel Injection, Solution, Concentrate
Product Images NDC 67457-781

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Docetaxel (NDC 67457-781). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mylan Institutional Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton Mdv (Image 01)

Carton Mdv (Image 01)
This is a one vial formulation of Docetaxel anhydrous USP in 20mg/mL quantity. Each mL contains 4mg anhydrous citric acid, 520mg polysorbate, and 395.5mg dehydrated alcohol. It is ready to add to infusion solution for administration. The multiple-dose vial must be used within 28 days after the initial puncture. It is a cytotoxic agent, must be kept out of children's reach, and should be stored between 15°C to 25°C (59°F to 77°F) and protected from light. The package insert contains complete instructions which include dosage and administration, directions for use, and handling. Overprinting along with batch details including LOT, EXP, GTINzIXXXXXXXXXXXXXXX, and S/NzZXXXXXXXXXX can be seen.*
FDA Label Image

Container Label (Image 02)

Container Label (Image 02)
NDC 67457-781-08 is a one vial formulation of Docetaxel Injection, USP. It is a cytotoxic agent available for intravenous infusion only, and is to be added to Mylan infusion solution. Each mL of the injection contains 20mg of docetaxel anhydrous USP along with polysorbate 80, dehydrated alcohol and anhydrous citric acid. The storage temperature recommended is between 15 to 25°C. Please refer to the package insert for instructions. The medication is manufactured in India and distributed by Mylan Institutional LLC. Lot number is available in the text.*
FDA Label Image

Structure (Image 03)

FDA Label Image

Graph 1 (Image 04)

Graph 1 (Image 04)
This text may represent a chart or table showing DFS (Disease Free Survival) probability in percentage (%) over time in months (a8, 24, 30, 54, 60, and 66). However, due to the lack of further information and the errors in the text, a more accurate interpretation cannot be provided.*
FDA Label Image

Graph 2 (Image 05)

FDA Label Image

Graph 3 (Image 06)

FDA Label Image

Graph 4 (Image 07)

Graph 4 (Image 07)
The text seems to be a part of a graph or chart displaying the Cumulative probability and Survival time in months. It also includes the overall survival of the period and a Log.rank p value. It is not clear without further context what the numbers 9, 12, 15, 18, and 21 represent.*
FDA Label Image

Graph 5 (Image 08)

FDA Label Image

Graph 6 (Image 09)

Graph 6 (Image 09)
This is a graph showing probability on the y-axis and time in months on the x-axis. The value of the probability starts at 12%.*
FDA Label Image

Graph 7 (Image 10)

FDA Label Image

Graph 8 (Image 11)

FDA Label Image

Graph 9 (Image 12)

Graph 9 (Image 12)
This is a chart that shows the survival probability (in percentage) at different time points (24, 30, 36, and 42 months). The chart does not provide any information on what this data pertains to.*
FDA Label Image

Graph 10 (Image 13)

Graph 10 (Image 13)
This is a graph representing the survival probability (%) of patients in two different groups: TPF (n=255) and PF (n=2248). The X-axis shows the survival time in months and the Y-axis indicates the survival percentage. The graph shows the survival percentage at different time points (0, 6, 12, 18, 24, 30, 36, 42, 48, 54, and 60 months). The number of patients at risk is also shown for each time point.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.